公开(公告)号：US11712448B2

公开(公告)日：2023-08-01

申请号：US15106196

申请日：2014-12-19

申请人： ALGIPHARMA AS

发明人： Arne Dessen ,  Philip Rye

IPC分类号： A61K31/734 ,  A61P7/02 ,  A61K31/702 ,  A61M1/36 ,  A61L33/08 ,  A61K31/715

CPC分类号： A61K31/734 ,  A61K31/702 ,  A61K31/715 ,  A61L33/08 ,  A61M1/3673 ,  A61P7/02 ,  A61L33/08 ,  C08L5/04

摘要： The disclosure relates to an alginate oligomer of 2 to 75 monomer residues, wherein said monomer residues do not carry a sulphate group, for use as a blood anticoagulant in clinical and non-clinical applications, including in vivo, ex vivo and in vitro contexts. The invention further provides for the use of such an alginate oligomer in preparing a product or device having a reduced capacity to promote blood coagulation, wherein said alginate oligomer is provided at or on a surface of said product or device. Such products and devices form a further aspect of the invention.

公开(公告)号：US20220305050A1

公开(公告)日：2022-09-29

申请号：US17596741

申请日：2020-06-17

申请人： AlgiPharma AS

发明人： Rhodri Williams ,  Phillip Adrian Evans ,  Arne Dessen ,  Philip Rye

IPC分类号： A61K31/734 ,  A61P7/02

摘要： An alginate oligomer for use in the anticoagulation therapy of a human or non-human vertebrate subject at risk of blood clots which have an abnormally dense microstructure. In certain embodiments, the incidence of blood clots which have an abnormally dense microstructure in the subject is reduced and/or the occurrence of blood clots which have an abnormally dense microstructure in the subject is inhibited and/or the abnormal microstructure of the subject's clots is normalized. Corresponding methods of anticoagulation therapy and products of use therein are further provided.

公开(公告)号：US11413306B2

公开(公告)日：2022-08-16

申请号：US15766272

申请日：2016-10-06

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Philip Rye

IPC分类号： A61K31/734 ,  A61P31/10 ,  A61K9/00 ,  A61K45/06 ,  A61K31/165 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/7036 ,  A61K31/4178 ,  A61K31/365 ,  A61K31/4245 ,  A61K31/352 ,  A61K31/192 ,  A61K36/03 ,  A61K31/522 ,  A61K31/4422 ,  A61P31/04

摘要： The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject in need thereof. Also provided is an alginate oligomer for use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject and a product containing an alginate oligomer and further pharmaceutical for the treatment of intestinal microbial overgrowth and/or a CFTR modulator as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject.

公开(公告)号：US10751363B2

公开(公告)日：2020-08-25

申请号：US15560984

申请日：2016-03-23

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Astrid Hilde Myrset ,  Philip Rye

IPC分类号： A61K31/734 ,  A61K31/443 ,  A61K31/4245 ,  A61K31/47 ,  A61K45/06 ,  A61K31/4164 ,  A61K31/405 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/43 ,  A61K31/7036

摘要： A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.

公开(公告)号：US20180055873A1

公开(公告)日：2018-03-01

申请号：US15560984

申请日：2016-03-23

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Astrid Hilde Myrset ,  Philip Rye

IPC分类号： A61K31/734 ,  A61K45/06 ,  A61K31/4245 ,  A61K31/443 ,  A61K31/47

摘要： A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.

公开(公告)号：US11385174B2

公开(公告)日：2022-07-12

申请号：US17264559

申请日：2019-07-30

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Philip Rye ,  Paul Lewis

IPC分类号： G01N21/35 ,  G01N21/3577 ,  G01N33/487

摘要： Qualitative and quantitative methods are for the detection of alginate oligomers in body fluids based on analyzing the Fourier transform infrared spectroscopy (FTIR) spectrum of a body fluid sample, for example a sputum sample, at a specific wave number range and, more particularly, certain specific characteristic wavenumbers.

公开(公告)号：US20220074853A1

公开(公告)日：2022-03-10

申请号：US17264559

申请日：2019-07-30

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Philip Rye ,  Paul Lewis

IPC分类号： G01N21/3577 ,  G01N33/487

摘要： Qualitative and quantitative methods are for the detection of alginate oligomers in body fluids based on analyzing the Fourier transform infrared spectroscopy (FTIR) spectrum of a body fluid sample, for example a sputum sample, at a specific wave number range and, more particularly, certain specific characteristic wavenumbers.

公开(公告)号：US20190328833A1

公开(公告)日：2019-10-31

申请号：US16343568

申请日：2017-10-20

申请人： AlgiPharma AS

发明人： Elaine Ferguson ,  David William Thomas ,  Arne Dessen ,  Philip Rye

IPC分类号： A61K38/12 ,  A61K47/61 ,  A61P31/04

摘要： A polymyxin-alginate oligomer conjugate including a polymyxin-class antibiotic connected covalently to at least one alginate oligomer via a direct covalent bond or a covalent molecular linker, or a pharmaceutically acceptable salt, solvate, hydrate, diastereoisomer, tautomer, enantiomer or active metabolite thereof. Also provided are methods for the preparation of the conjugate, pharmaceutical compositions comprising the conjugate and the use thereof in a method for the treatment or prevention of a bacterial infection in a subject with, suspected to have, or at risk of, a bacterial infection.